

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Fust Matthew K</u>  (Last) (First) (Middle) <u>C/O CRINETICS PHARMACEUTICALS, INC.</u> <u>6055 LUSK BOULEVARD</u>  (Street) <u>SAN DIEGO CA 92121</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [ CRNX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/20/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		
Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/20/2024		M		12,500	A	\$23.24	31,036	D	
Common Stock	03/20/2024		S <sup>(1)</sup>		12,500	D	\$43.57 <sup>(2)</sup>	18,536	D	
Common Stock	03/20/2024		M		12,500	A	\$23.23	31,036	D	
Common Stock	03/20/2024		S <sup>(1)</sup>		12,500	D	\$43.57 <sup>(2)</sup>	18,536	D	
Common Stock	03/20/2024		M		17,500	A	\$20.23	36,036	D	
Common Stock	03/20/2024		S <sup>(1)</sup>		17,500	D	\$43.58 <sup>(3)</sup>	18,536	D	
Common Stock	03/20/2024		M		17,500	A	\$18.29	36,036	D	
Common Stock	03/20/2024		S <sup>(1)</sup>		17,500	D	\$45.5	18,536	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$23.24	03/20/2024		M		12,500		(4)	06/20/2029	Common Stock	12,500	\$0.00	0	D	
Stock Option (right to buy)	\$23.23	03/20/2024		M		12,500		(4)	06/18/2030	Common Stock	12,500	\$0.00	0	D	
Stock Option (right to buy)	\$20.23	03/20/2024		M		17,500		(4)	06/21/2031	Common Stock	17,500	\$0.00	0	D	
Stock Option (right to buy)	\$18.29	03/20/2024		M		17,500		(4)	06/16/2032	Common Stock	17,500	\$0.00	0	D	

**Explanation of Responses:**

- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of \$43.57 per share. The range of sales prices on the transaction date was \$42.70 to \$44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of \$43.58 per share. The range of sales prices on the transaction date was \$42.70 to \$44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

**Remarks:**

/s/ Marc Wilson, as attorney-in-fact 03/22/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**